

FOR IMMEDIATE RELEASE:

New Executive Committee Members Named to Clinical Trials Transformation Initiative (CTTI)

Durham, North Carolina - May 7, 2013 - The Clinical Trials Transformation Initiative (CTTI) has named new members to its Executive Committee, expanding the breadth of expertise for leaders advising CTTI on its strategy for transforming clinical research.

"Clinical trials provide critical evidence about which strategies and therapies are most effective to diagnose and treat patients," said Robert Califf, M.D., co-chair of the CTTI Executive Committee, vice chancellor for clinical and translational research at Duke University Medical Center, and director of the Duke Translational Medicine Institute.

"It is important that trials are done in such a way as to ensure data are reliable, patients are protected, and limited resources are well used," Califf said. "CTTI is committed to working with all stakeholders involved in clinical research to shape the clinical trials enterprise of the future where this is the norm."

Established by the Food and Drug Administration and Duke University as a public-private partnership in 2007, CTTI comprises more than 60 member organizations working to identify and promote practices that will increase the quality and efficiency of clinical trials.

"The Clinical Trials Transformation Initiative continues to focus its efforts on enhancing the efficiency and quality of clinical trials by addressing issues in areas of critical public health importance, such as exploring new approaches for accelerating the development of new antibacterial drugs," said Rachel Sherman, M.D., director for the Office of Medical Policy in the FDA's Center for Drug Evaluation and Research and co-chair of the CTTI Executive Committee. She continued, "Because of the broad membership, this group is in a unique position to drive change so that we have a high quality clinical trial system that is patient-centered, efficient, and produces reliable results."

The CTTI Executive Committee includes accomplished U.S. and international leaders from government, non-profit and private sector organizations who are dedicated to finding solutions which will ultimately result in better care to patients.

The new CTTI Executive Committee members are:

Dalvir Gill, PhD
Chief Executive Officer
TransCelerate Biopharma Inc.

Richard Kuntz, M.D., MSc
Chief Medical Officer
Medtronic, Inc.

Deven McGraw, JD, MPH, LLM
Director, Health Privacy Project
Center for Democracy & Technology

Joe Selby, M.D., MPH
Executive Director
Patient-Centered Outcomes Research Institute (PCORI)

William Shrank M.D., MSHS
Director, Rapid Cycle Evaluation Group
Center for Medicare and Medicaid Innovation
Centers for Medicare and Medicaid Services

Also, Veronica Todaro, MPH, director of national programs for the Parkinson's Disease Foundation and co-chair of the CTTI Patient Leadership Council (PLC), was recently named as the PLC liaison to the Executive Committee.

More information about CTTI and the Executive Committee members is available on the CTTI website at <http://www.ctti-clinicaltrials.org/who-we-are/organizational-structure/executive-committee>.

Contact:
Leanne Madre
Director of Strategy, CTTI
leanne.madre@duke.edu

###